Therefore, inhibitors of epigenetic regulators not only suppress tumor progression but also simultaneously increase PD-L1 expression; they could potentially be combined with anti-PD-L1 immunotherapy to improve therapeutic response. The gene discussed is CD274; the disease is neoplasm.